The presence of low bicarbonate levels indicates a metabolic acidosis, which strongly indicates the possibility of mesenteric ischemia.

Bowel Ischaemia: Types, Features, and Management

Bowel ischaemia is a condition that can affect the lower gastrointestinal tract and can result in various clinical conditions. Although there is no standard classification, it is helpful to categorize cases into three main conditions: acute mesenteric ischaemia, chronic mesenteric ischaemia, and ischaemic colitis. Common predisposing factors for bowel ischaemia include increasing age, atrial fibrillation (particularly for mesenteric ischaemia), other causes of emboli, cardiovascular disease risk factors, and cocaine use. Common features of bowel ischaemia include abdominal pain, rectal bleeding, diarrhea, fever, and elevated white blood cell count associated with lactic acidosis.

Acute mesenteric ischaemia is typically caused by an embolism resulting in occlusion of an artery that supplies the small bowel, such as the superior mesenteric artery. Urgent surgery is usually required for management, and prognosis is poor, especially if surgery is delayed. Chronic mesenteric ischaemia is a relatively rare clinical diagnosis that may be thought of as intestinal angina, with intermittent abdominal pain occurring. Ischaemic colitis describes an acute but transient compromise in the blood flow to the large bowel, which may lead to inflammation, ulceration, and hemorrhage.

Diagnosis of bowel ischaemia is typically done through CT scans. In acute mesenteric ischaemia, the abdominal pain is typically severe, of sudden onset, and out-of-keeping with physical exam findings. In chronic mesenteric ischaemia, the symptoms are non-specific. In ischaemic colitis, thumbprinting may be seen on abdominal x-ray due to mucosal edema/haemorrhage. Management of bowel ischaemia is usually supportive, but surgery may be required in a minority of cases if conservative measures fail. Indications for surgery would include generalized peritonitis, perforation, or ongoing hemorrhage.

A suitable medication would have been a DDP-4 inhibitor, glitazone, or sulfonylurea. The use of GLP-1 receptor agonists is not appropriate, as it is only recommended when triple therapy with metformin and two other oral drugs has failed.

NICE updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022, reflecting advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors. The first-line drug of choice remains metformin, which should be titrated up slowly to minimize gastrointestinal upset. HbA1c targets should be agreed upon with patients and checked every 3-6 months until stable, with consideration for relaxing targets on a case-by-case basis. Dietary advice includes encouraging high fiber, low glycemic index sources of carbohydrates and controlling intake of foods containing saturated fats and trans fatty acids. Blood pressure targets are the same as for patients without type 2 diabetes, and antiplatelets should not be offered unless a patient has existing cardiovascular disease. Only patients with a 10-year cardiovascular risk > 10% should be offered a statin, with atorvastatin 20mg as the first-line choice.

To avoid the possibility of masking serious underlying pathology like gastric cancer, patients who are taking proton pump inhibitors or H2 receptor blockers should discontinue their use at least two weeks before undergoing an endoscopy.

Management of Dyspepsia and Referral for Possible Cancer

Dyspepsia is a common symptom that can be caused by various factors, including medication and lifestyle choices. However, it can also be a sign of underlying conditions such as stomach or oesophageal cancer. The 2015 NICE guidelines provide updated advice on when urgent referral for endoscopy is necessary. Patients with dysphagia or an upper abdominal mass consistent with stomach cancer should be referred urgently. Patients aged 55 years or older with weight loss and upper abdominal pain, reflux, or dyspepsia should also be referred urgently. Non-urgent referrals include patients with haematemesis or those with treatment-resistant dyspepsia, upper abdominal pain with low haemoglobin levels, or raised platelet count with other symptoms.

For patients with undiagnosed dyspepsia, a step-wise approach is recommended. First, medications should be reviewed for possible causes. Lifestyle advice should also be given. If symptoms persist, a trial of full-dose proton pump inhibitor for one month or a ‘test and treat’ approach for H. pylori can be tried. If symptoms persist after either approach, the alternative should be attempted. Testing for H. pylori infection can be done using a carbon-13 urea breath test, stool antigen test, or laboratory-based serology. If symptoms resolve following test and treat, there is no need to check for H. pylori eradication. However, if repeat testing is required, a carbon-13 urea breath test should be used.

Topical glyceryl trinitrate is used to treat chronic anal fissure.

Understanding Anal Fissures: Causes, Symptoms, and Treatment

Anal fissures are tears in the lining of the distal anal canal that can be either acute or chronic. Acute fissures last for less than six weeks, while chronic fissures persist for more than six weeks. The most common risk factors for anal fissures include constipation, inflammatory bowel disease, and sexually transmitted infections such as HIV, syphilis, and herpes.

Symptoms of anal fissures include painful, bright red rectal bleeding, with around 90% of fissures occurring on the posterior midline. If fissures are found in other locations, underlying causes such as Crohn’s disease should be considered.

Management of acute anal fissures involves softening stool, dietary advice, bulk-forming laxatives, lubricants, topical anaesthetics, and analgesia. For chronic anal fissures, the same techniques should be continued, and topical glyceryl trinitrate (GTN) is the first-line treatment. If GTN is not effective after eight weeks, surgery (sphincterotomy) or botulinum toxin may be considered, and referral to secondary care is recommended.

In summary, anal fissures can be a painful and uncomfortable condition, but with proper management, they can be effectively treated. It is important to identify and address underlying risk factors to prevent the development of chronic fissures.

The sole recommended test for H. pylori after eradication therapy is the urea breath test. It should be noted that H. pylori serology will still show positive results even after eradication. In such cases, a stool antigen test, rather than culture, may be a suitable alternative.

Tests for Helicobacter pylori

There are several tests available to diagnose Helicobacter pylori infection. One of the most common tests is the urea breath test, where patients consume a drink containing carbon isotope 13 (13C) enriched urea. The urea is broken down by H. pylori urease, and after 30 minutes, the patient exhales into a glass tube. Mass spectrometry analysis calculates the amount of 13C CO2, which indicates the presence of H. pylori. However, this test should not be performed within four weeks of treatment with an antibacterial or within two weeks of an antisecretory drug.

Another test is the rapid urease test, also known as the CLO test. This involves mixing a biopsy sample with urea and a pH indicator. If there is a color change, it indicates the presence of H. pylori urease activity. Serum antibody tests can also be used, but they remain positive even after eradication. Culture of gastric biopsy can provide information on antibiotic sensitivity, while histological evaluation alone can be done through gastric biopsy. Lastly, the stool antigen test has a sensitivity of 90% and specificity of 95%.

Overall, these tests have varying levels of sensitivity and specificity, and the choice of test depends on the patient’s clinical presentation and the availability of resources.

The appropriate surgical procedure for a patient with caecal, ascending or proximal transverse colon cancer is a right hemicolectomy. This involves removing the cecum, ascending colon, and proximal third of the transverse colon. If the cancer is located at the hepatic flexure, an extended right hemicolectomy may be necessary. Hartmann’s procedure is reserved for emergencies such as bowel obstruction or perforation and involves complete resection of the rectum and sigmoid colon with the formation of an end colostomy. A high anterior resection is used for upper rectal tumors, while a left hemicolectomy is used for distal two-thirds of the transverse colon and descending colon tumors. A low anterior resection is used for low rectal tumors, but none of these procedures are appropriate for a patient with a mass in the hepatic flexure.

Colorectal cancer is typically diagnosed through CT scans and colonoscopies or CT colonography. Patients with tumors below the peritoneal reflection should also undergo MRI to evaluate their mesorectum. Once staging is complete, a treatment plan is formulated by a dedicated colorectal MDT meeting.

For colon cancer, surgery is the primary treatment option, with resectional surgery being the only cure. The procedure is tailored to the patient and tumor location, with lymphatic chains being resected based on arterial supply. Anastomosis is the preferred method of restoring continuity, but in some cases, an end stoma may be necessary. Chemotherapy is often offered to patients with risk factors for disease recurrence.

Rectal cancer management differs from colon cancer due to the rectum’s anatomical location. Tumors can be surgically resected with either an anterior resection or an abdomino-perineal excision of rectum (APER). A meticulous dissection of the mesorectal fat and lymph nodes is integral to the procedure. Neoadjuvant radiotherapy is often offered to patients prior to resectional surgery, and those with obstructing rectal cancer should have a defunctioning loop colostomy.

Segmental resections based on blood supply and lymphatic drainage are the primary operations for cancer. The type of resection and anastomosis depend on the site of cancer. In emergency situations where the bowel has perforated, an end colostomy is often safer. Left-sided resections are more risky, but ileo-colic anastomoses are relatively safe even in the emergency setting and do not need to be defunctioned.

Biliary Colic and Other Abdominal Conditions: A Brief Overview

Biliary colic, diverticulitis, chronic pancreatitis, ulcerative colitis, and coeliac disease are all conditions that can cause abdominal pain and discomfort. Understanding the risk factors, symptoms, and diagnostic criteria for each can help healthcare professionals make accurate diagnoses and provide appropriate treatment. Biliary colic, for example, is characterized by severe, constant pain in the epigastrium or right upper quadrant, often accompanied by nausea and vomiting. Diverticulitis, on the other hand, typically presents with left lower quadrant pain and changes in bowel habits. Chronic pancreatitis is associated with intermittent attacks of severe pain in the mid-abdomen or left upper abdomen, while ulcerative colitis is characterized by rectal bleeding, frequent stools, and mucus discharge. Coeliac disease, the most common food intolerance worldwide, can present with a range of gastrointestinal and extraintestinal symptoms. By understanding the unique features of each condition, healthcare professionals can provide effective care and improve patient outcomes.

Acute mesenteric ischaemia (AMI) is a rare but potentially life-threatening condition caused by inadequate blood flow through the mesenteric vessels, leading to ischaemia and gangrene of the bowel wall. It can be classified as either arterial or venous, with embolic phenomena being the most common cause. Symptoms include sudden and severe abdominal pain, vomiting, and diarrhoea, with physical signs developing late in the disease process. Early and aggressive diagnosis and treatment are crucial to reduce mortality, but once bowel wall infarction has occurred, the mortality rate may be as high as 90%. Appendicitis, diverticulitis, pseudomembranous colitis, and ruptured AAA are important differential diagnoses to consider.

The man in this scenario is experiencing Charcot’s triad, which includes right upper quadrant pain, fever, and jaundice. These symptoms suggest that he may have ascending cholangitis, which is caused by a bacterial infection in the biliary tree due to obstruction from biliary stasis (likely caused by his gallstones). Treatment involves resuscitation, IV antibiotics, and biliary drainage.

Understanding Ascending Cholangitis

Ascending cholangitis is a bacterial infection that affects the biliary tree, with E. coli being the most common culprit. This condition is often associated with gallstones, which can predispose individuals to the infection. Patients with ascending cholangitis may present with Charcot’s triad, which includes fever, right upper quadrant pain, and jaundice. However, this triad is only present in 20-50% of cases. Other common symptoms include hypotension and confusion. In severe cases, Reynolds’ pentad may be observed, which includes the additional symptoms of hypotension and confusion.

To diagnose ascending cholangitis, ultrasound is typically used as a first-line investigation to look for bile duct dilation and stones. Raised inflammatory markers may also be observed. Treatment involves intravenous antibiotics and endoscopic retrograde cholangiopancreatography (ERCP) after 24-48 hours to relieve any obstruction.

Overall, ascending cholangitis is a serious condition that requires prompt diagnosis and treatment. Understanding the symptoms and risk factors associated with this condition can help individuals seek medical attention early and improve their chances of a successful recovery.

The urea breath test is a non-invasive, highly specific and sensitive method. Therefore, there is no need for an endoscopy. Instead, an alternative option is to use stool antigen instead of culture.

Tests for Helicobacter pylori

There are several tests available to diagnose Helicobacter pylori infection. One of the most common tests is the urea breath test, where patients consume a drink containing carbon isotope 13 (13C) enriched urea. The urea is broken down by H. pylori urease, and after 30 minutes, the patient exhales into a glass tube. Mass spectrometry analysis calculates the amount of 13C CO2, which indicates the presence of H. pylori. However, this test should not be performed within four weeks of treatment with an antibacterial or within two weeks of an antisecretory drug.

Another test is the rapid urease test, also known as the CLO test. This involves mixing a biopsy sample with urea and a pH indicator. If there is a color change, it indicates the presence of H. pylori urease activity. Serum antibody tests can also be used, but they remain positive even after eradication. Culture of gastric biopsy can provide information on antibiotic sensitivity, while histological evaluation alone can be done through gastric biopsy. Lastly, the stool antigen test has a sensitivity of 90% and specificity of 95%.

Overall, these tests have varying levels of sensitivity and specificity, and the choice of test depends on the patient’s clinical presentation and the availability of resources.